Finance

Lists
Q1 2027 earnings • released • EPS beat +6.93% • Revenue beat +6.18%
See results
LUPIN:NSE
Lupin Ltd
₹2,370.70
-0.60%
(-14.30) 1D
Aug 7, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for LUPIN...
Open
₹2,410.00
High
₹2,410.00
Low
₹2,346.00
Mkt. cap
1.08T
Avg. vol.
905.90K
Volume
2.05M
Dividend
0.76%
Quarterly dividend
₹4.50
Ex-dividend date
Jul 17, 2026
P/E ratio
20.36
52-wk high
₹2,529.50
52-wk low
₹1,855.00
EPS
₹116.44
Shares outstanding
452.41M
No. of employees
26K
Open
₹2,410.00
High
₹2,410.00
Low
₹2,346.00
Mkt. cap
1.08T
Avg. vol.
905.90K
Volume
2.05M
Dividend
0.76%
Quarterly dividend
₹4.50
Ex-dividend date
Jul 17, 2026
P/E ratio
20.36
52-wk high
₹2,529.50
52-wk low
₹1,855.00
EPS
₹116.44
Shares outstanding
452.41M
No. of employees
26K
News stories
From sources across the web
Profile
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is primarily a manufacturer of generic drugs, covering therapeutic areas such as paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.The company operates in multiple international markets including the United States, Japan, Europe, and Australia.. Wikipedia
About Lupin Ltd
CEOVinita D. Gupta
Employees26K
Founded1968
HeadquartersMumbai, Maharashtra, India
SectorPharmaceutical industry
Websitelupin.com
Last report
Aug 7, 2026
Fiscal period
Q1 2027
EPS / Est. (INR)
₹30.89 / ₹28.89
+6.93%beat
Revenue / Est. (INR)
84.07B / 79.18B
+6.18%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
70.48B
71.68B
74.75B
84.07B
Cost of goods sold
18.25B
18.78B
24.90B
20.89B
Cost of revenue
18.25B
18.78B
24.90B
20.89B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.06B
11.43B
13.85B
13.83B
Operating expense
34.02B
33.93B
31.74B
41.77B
Total operating expenses
52.27B
52.71B
56.64B
62.66B
Operating income
18.21B
18.97B
18.10B
20.99B
Other non operating income
900.00M
1.15B
-2.87B
-
EBT including unusual items
20.07B
15.22B
19.28B
20.17B
EBT excluding unusual items
20.07B
19.49B
19.91B
20.17B
Income tax expense
5.22B
3.42B
4.59B
6.00B
Effective tax rate
26.02%
22.44%
23.82%
29.76%
Other operating expenses
19.80B
19.37B
14.55B
23.41B
Net income
14.78B
11.76B
14.60B
14.15B
Net profit margin
20.97%
16.40%
19.54%
16.83%
Earnings per share
32.28
32.18
34.75
30.89
Interest and investment income
-
-
2.17B
-
Interest expense
-1.08B
-1.15B
-633.10M
-1.10B
Net interest expenses
-1.08B
-1.15B
1.54B
-1.10B
Depreciation and amortization charges
3.17B
3.13B
3.34B
4.53B
EBITDA
21.29B
21.20B
20.81B
24.12B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps